PriceTargets.com logo

Esperion Therapeutics - ESPR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.20
  • Forecasted Upside: 67.66%
  • Number of Analysts: 4
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.68 As of 01/27/2023 01:00 AM ET
▲ +0.03 (0.45%)

This chart shows the closing price for ESPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Esperion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESPR

Analyst Price Target is $11.20
▲ +67.66% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $11.20, with a high forecast of $22.00 and a low forecast of $6.00. The average price target represents a 67.66% upside from the last price of $6.68.

This chart shows the closing price for ESPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Esperion Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 3 sell ratings
Ratings as of
8/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 3 sell ratings
Ratings as of
11/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 3 sell ratings
Ratings as of
2/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
5/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
Ratings as of
8/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
12/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/2/2022Morgan StanleyBoost TargetUnderweight$7.00 ➝ $9.00Low
8/9/2022CowenLower Target$13.00N/A
8/3/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform$7.00 ➝ $6.00Low
7/15/2022Morgan StanleyBoost TargetUnderweight$5.00 ➝ $7.00Low
5/4/2022JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$6.00High
3/10/2022HC WainwrightInitiated CoverageBuy$22.00Medium
1/14/2022Credit Suisse GroupLower TargetNeutral$8.00 ➝ $6.00Medium
1/12/2022Northland SecuritiesLower Target$10.00 ➝ $5.00Medium
12/9/2021Needham & Company LLCLower TargetBuy$20.00 ➝ $12.00High
12/6/2021Credit Suisse GroupLower TargetNeutral$11.00 ➝ $8.00High
10/19/2021CowenLower TargetPositive ➝ Outperform$60.00 ➝ $30.00High
10/18/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral$28.00 ➝ $11.00High
10/14/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$17.00 ➝ $11.00High
9/22/2021The Goldman Sachs GroupLower TargetSell$16.00 ➝ $8.00High
9/14/2021JMP SecuritiesReiterated RatingBuy$90.00Medium
8/4/2021Morgan StanleyLower TargetEqual Weight$22.00 ➝ $17.00Medium
8/3/2021Needham & Company LLCLower TargetStrong-Buy$134.00 ➝ $114.00Medium
5/11/2021Stifel NicolausReiterated RatingBuy ➝ Hold$37.00 ➝ $20.00Low
5/5/2021BTIG ResearchLower Target$90.00 ➝ $71.00High
5/5/2021Northland SecuritiesLower TargetMarket Perform$30.00 ➝ $24.00High
5/5/2021Credit Suisse GroupLower TargetOutperform$45.00 ➝ $36.00High
5/5/2021Morgan StanleyLower TargetEqual Weight$30.00 ➝ $22.00High
5/5/2021JMP SecuritiesLower TargetMarket Outperform$191.00 ➝ $111.00High
5/5/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $20.00High
3/11/2021Morgan StanleyInitiated CoverageEqual Weight$30.00Medium
2/25/2021Needham & Company LLCLower TargetStrong-Buy$150.00 ➝ $134.00High
2/12/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $30.00Low
2/9/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$44.00 ➝ $24.00Low
1/15/2021Bank of AmericaDowngradeBuy ➝ Neutral$52.00 ➝ $35.00High
11/10/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00Medium
10/15/2020Bank of AmericaLower TargetBuy$55.00 ➝ $52.00Low
9/29/2020JPMorgan Chase & Co.Initiated CoverageSell$35.00Low
8/17/2020Bank of AmericaLower TargetBuy$60.00 ➝ $55.00Low
8/11/2020Needham & Company LLCReiterated RatingBuy$158.00High
8/10/2020Stifel NicolausReiterated RatingBuy$75.00High
8/10/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$83.00 ➝ $45.00High
6/29/2020Credit Suisse GroupInitiated CoverageBuy$83.00High
6/26/2020Stifel NicolausReiterated RatingBuy$75.00High
6/23/2020Northland SecuritiesInitiated CoverageHold$42.00High
6/9/2020Credit Suisse GroupReiterated RatingBuy$87.00Medium
5/7/2020Jefferies Financial GroupLower TargetBuy$85.00 ➝ $70.00High
5/7/2020Needham & Company LLCReiterated RatingBuyHigh
5/7/2020Northland SecuritiesReiterated RatingHold$42.00High
5/7/2020CitigroupBoost TargetBuy$46.00 ➝ $56.00High
5/6/2020Stifel NicolausReiterated RatingBuy$76.00High
4/20/2020Stifel NicolausReiterated RatingBuyLow
4/20/2020Needham & Company LLCReiterated RatingBuy$158.00Low
4/16/2020Northland SecuritiesLower TargetMarket Perform$60.00 ➝ $42.00High
4/6/2020Needham & Company LLCReiterated RatingBuy$158.00High
4/1/2020Bank of AmericaInitiated CoverageBuy$50.00High
3/31/2020Needham & Company LLCReiterated RatingBuy$158.00High
3/17/2020CitigroupUpgradeNeutral ➝ BuyHigh
2/28/2020JPMorgan Chase & Co.Boost TargetNeutral$46.00 ➝ $47.00Low
2/27/2020CowenReiterated RatingBuy$87.00Medium
2/24/2020Needham & Company LLCBoost TargetStrong-Buy$144.00 ➝ $158.00Medium
2/24/2020JMP SecuritiesReiterated RatingOutperform$191.00Medium
2/23/2020Stifel NicolausReiterated RatingBuy$83.00Medium
2/23/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$60.00Medium
2/19/2020BTIG ResearchReiterated RatingBuy$90.00Medium
2/14/2020CitigroupDowngradeBuy ➝ Neutral$73.00 ➝ $82.00High
1/31/2020Chardan CapitalReiterated RatingHold$65.00High
11/6/2019CowenReiterated RatingBuyLow
9/17/2019Stifel NicolausLower TargetBuy$112.00 ➝ $70.00Low
9/16/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$55.00 ➝ $45.00Medium
8/29/2019Northland SecuritiesReiterated RatingBuyHigh
8/8/2019Northland SecuritiesReiterated RatingBuyMedium
7/18/2019CowenReiterated RatingBuy$80.00Low
6/14/2019Northland SecuritiesSet TargetBuy$65.00Medium
6/13/2019Stifel NicolausReiterated RatingBuyLow
6/13/2019CowenReiterated RatingBuy$85.00Medium
5/29/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$50.00Medium
5/28/2019CitigroupSet TargetBuy$73.00High
5/6/2019Credit Suisse GroupBoost TargetOutperform$79.00 ➝ $90.00Medium
5/6/2019Bank of AmericaUpgradeUnderperform ➝ NeutralLow
5/5/2019CowenSet TargetBuy$94.00High
4/26/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$50.00Low
4/2/2019Northland SecuritiesSet TargetBuy$65.00Low
3/29/2019Stifel NicolausReiterated RatingBuy$112.00Low
3/14/2019Chardan CapitalReiterated RatingHold$50.00Medium
3/13/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$38.00 ➝ $47.00High
3/1/2019Northland SecuritiesReiterated RatingBuy$65.00Low
1/15/2019CowenReiterated RatingBuy$94.00Low
1/7/2019Needham & Company LLCBoost TargetStrong-Buy$94.00 ➝ $114.00Low
12/13/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$45.00High
12/10/2018Stifel NicolausBoost TargetBuy ➝ Buy$89.00 ➝ $104.00Medium
10/29/2018Northland SecuritiesUpgradeMarket Perform ➝ Outperform$65.00High
10/26/2018CowenSet TargetBuy$82.00Low
10/16/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$82.00High
9/14/2018Stifel NicolausInitiated CoverageBuy$89.00High
8/17/2018CitigroupUpgradeNeutral ➝ Buy$57.00 ➝ $75.00Low
8/6/2018CowenReiterated RatingBuy$95.00Low
7/20/2018Chardan CapitalUpgradeHold$32.50Low
7/11/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformMedium
5/16/2018UBS GroupSet TargetBuy$90.00 ➝ $75.00Low
5/4/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$108.00 ➝ $73.00N/A
5/3/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$100.54 ➝ $41.00High
5/3/2018Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$100.00 ➝ $75.00High
5/2/2018Bank of AmericaReiterated RatingBuy ➝ UnderperformHigh
4/19/2018Northland SecuritiesBoost TargetBuy$100.00 ➝ $121.00Low
3/27/2018Chardan CapitalBoost TargetNeutral ➝ Neutral$75.00 ➝ $100.00Low
3/9/2018Deutsche Bank AktiengesellschaftBoost TargetBuy$100.00Low
3/8/2018JMP SecuritiesBoost TargetOutperform$60.00 ➝ $153.00High
3/7/2018Stifel NicolausSet TargetBuy$105.00High
2/21/2018UBS GroupSet TargetNeutral ➝ Neutral$88.00 ➝ $90.00High
2/21/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $65.00High
2/21/2018Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$81.00 ➝ $94.00Low
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Esperion Therapeutics logo
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Read More

Today's Range

Now: $6.68
Low: $6.58
High: $6.89

50 Day Range

MA: $6.50
Low: $5.09
High: $7.49

52 Week Range

Now: $6.68
Low: $3.28
High: $8.87

Volume

955,045 shs

Average Volume

1,318,018 shs

Market Capitalization

$492.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Esperion Therapeutics?

The following Wall Street research analysts have issued stock ratings on Esperion Therapeutics in the last year: Cowen Inc., Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, and StockNews.com.
View the latest analyst ratings for ESPR.

What is the current price target for Esperion Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Esperion Therapeutics in the last year. Their average twelve-month price target is $11.20, suggesting a possible upside of 67.7%. HC Wainwright has the highest price target set, predicting ESPR will reach $22.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $6.00 for Esperion Therapeutics in the next year.
View the latest price targets for ESPR.

What is the current consensus analyst rating for Esperion Therapeutics?

Esperion Therapeutics currently has 2 sell ratings, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares.
View the latest ratings for ESPR.

What other companies compete with Esperion Therapeutics?

Other companies that are similar to Esperion Therapeutics include Veru, Akouos, GH Research, Design Therapeutics and 2seventy bio. Learn More about companies similar to Esperion Therapeutics.

How do I contact Esperion Therapeutics' investor relations team?

Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is (734) 887-3903 and its investor relations email address is [email protected] The official website for Esperion Therapeutics is www.esperion.com. Learn More about contacing Esperion Therapeutics investor relations.